Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1236-1242

  Uusitupa, Matti I J ^a   Niskanen, Leo ^a   Luoma, Jukka ^a   Vilja, Pekka ^b   Mercuri, Michele ^c   Rauramaa, Rainer ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

atherosclerosis; cardiovascular mortality; morbidity; non insulin dependent diabetes mellitus; oxidized LDL

Indexed keywords

AUTOANTIBODY; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; COMMON CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE;

EID: 0029819268     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1236     Document Type: Article

References (45)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035-2038.
2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall Study. BMJ. 1983;287:867-870.
3. Krolewski AS, Kosinski EI, Warram JH, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin dependent diabetes mellitus. Am J Cardiol. 1987;59:750-755.
4. Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle aged diabetic men: a general population study. BMJ. 1989;299:1127-1131.
5. Manson JE, Colditz GA, Stampfer MJ, Willet WC, Krolweski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-on set diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
6. Stamler J, Vaccaro O, Neaton J, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434-449.
7. Pyörälä K, Laakso M, Uusitupa M, Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
8. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1984.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
10. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
11. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 1992;15:1835-1843.
12. Witztum JL, Steinbrecher UP, Fisher M, Kesäniemi A. Nonenzymatic glucosylation of homologous LDL and albumin render them immunogenic in the guinea pig. Proc Natl Acad Sci USA. 1983;80:2757-2761.
13. Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes. 199l;40:405-412.
14. Deslypere J-P. Modified lipoproteins in diabetes. J Intern Med. 1994;236:69-74.
15. Bellemo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes. 1995;44:60-66.
16. Rabini RA, Fumelli P, Galassi R, Dousset N, Taus M, Ferretti G, Mazzanti L, Curatola G, Solera ML, Valdiguie P. Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. Metabolism. 1994;43:1470-1474.
17. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssönen K, Palinski W, Witztum JL. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
18. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb. 1994;14:1892-1899.
19. Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994;154:2605-2609.
20. Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middleaged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia. 1985;28:22-27.
21. Partanen J, Niskanen L, Lehtinen J, Siitonen O, Mervaala E, Uusitupa M. Natural history of peripheral neuropathy in NIDDM. N Engl J Med. 1995;333:89-94.
22. WHO Expert Committee on Diabetes Mellitus. 2nd report. Geneva, Switzerland: World Health Organization; 1980. Technical report series No. 646.
23. Penttilä IM, Voutilainen E, Laitinen P, Juutilainen P. Comparison of different analytical and precipitation methods for the direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest. 1981;41:353-360.
24. Röschlau P, Bernt E, Gruber W. Enzymatische Bestimmung des Gesamtcholesterins in serum. Z Klin Chem Biochem. 1974;12:403-407.
25. Wahlefield AW. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer HU, ed. Methods in Enzymatic Analysis. New York, NY: Academic Press; 1974:1831-1835.
26. Mercuri M. Noninvasive imaging protocols to detect and monitor carotid atherosclerosis progression. Am J Hypertens. 1994;7:23-29.
27. Mercuri M, Bond MG, Nichols FT, Carr AA, Flack JM, Byington R, Raines J, for the MIDAS Group. Baseline reproducibility of B-mode ultrasound imaging measurements of carotid intima-media thickness: the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). J Cardiovasc Diagn Proc. 1993;11:241-256.
28. Pignoli P, Tremoli E, Poli A, Oreste P, Faoletti R. Intimai plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation. 1986;74:1399-1406.
29. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SA, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86:1372-1376.
30. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidaemic rabbits. Science. 1988;241:215-218.
31. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbits and man. J Clin Invest. 1989;84:1086-1097.
32. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis. 1990;10:336-349.
33. Parums DV, Brown DL, Mitchinson MJ. Serurn antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990;114:383-387.
34. Palinski W, Ylä-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
35. Ylä-Herttuala S, Palinski W, Butler SW, Picard S. Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
36. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Antioxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993;23:95-101.
37. Fontbonne A, Eschwege E, Cammbien F, Richard J-L, Ducimetiere P, Thibult N, Warnet J-M, Claude J-R, Rosselin G-E. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia. 1989;32:300-304.
38. Laakso M, Lento S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421-1430.
39. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
40. Niskanen LK, Uusitupa MI, Sarlund H, Siitonen O, Pyop̈rälä K. Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care. 1990;13:41-48.
41. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M. Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke. In press.
42. Craven TE, Ruy JE, Espeland MA, Kahl FR, McKinney WM, Toole JF, McMahan MR, Thompson CJ, Heiss G, Grouse JR. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis. Circulation. 1990;82:1230-1242.
43. Salonen JT, Salonen R. Risk factors for carotid and femoral atherosclerosis in hypercholesterolaemic men. Int J Med. 1994;236:561-566.
44. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and cardiolipin in systemic lupus erythematosus. Lancet. 1993;341:923-925.
45. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Preeclarnpsia and serum antibodies to oxidised low-density lipoprotein. Lancet. 1994;343:645-646.